Low Molecular Weight Conjugates for Glucose-Responsive Insulin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems, particularly for diabetes treatment, fail to release insulin in proportion to varying blood glucose concentrations, leading to uncontrolled and undesirable slow release of insulin, which is not sufficient to prevent pathological sequelae associated with diabetes.
Innovation Solution
Development of conjugates with low molecular weight polymeric frameworks that include multiple affinity ligands, capable of forming insoluble cross-linked materials with multivalent cross-linking agents, allowing controlled release of insulin in response to glucose concentrations, thereby mimicking physiological insulin delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high molecular weight natural carbohydrates (dextran, glycogen) are used as conjugates, then the conjugates can form insoluble cross-linked materials with multivalent cross-linking agents, but the conjugates suffer from enzymatic degradation and production challenges
Solution Approach 1:
The patent changes the molecular weight parameter of the carbohydrate conjugates from high molecular weight (natural polymers) to low molecular weight (synthetic polymers with controlled degrees of polymerization). This parameter change resolves the contradiction by providing conjugates that are small enough to avoid enzymatic degradation and easier to manufacture with controlled structures, while still capable of forming insoluble cross-linked materials through multivalent cross-linking
Solution Approach 2:
The patent employs synthetic carbohydrate polymers with controlled low molecular weights that are designed to be metabolized and cleared from the body after their functional purpose is fulfilled. These synthetic conjugates replace difficult-to-manufacture natural polymers with more accessible,可控 synthetic alternatives that maintain the desired cross-linking functionality without the production challenges of natural polymer extraction and purification
2Duration of action of moving object
If conjugates are designed to release insulin slowly and continuously, then the release is independent of blood glucose concentrations, but the release is not proportional to varying glucose levels, leading to uncontrolled insulin delivery
Solution Approach 1:
The patent incorporates a feedback mechanism where the insulin release rate is regulated by glucose levels through the use of glucose-responsive multivalent cross-linking agents. These agents dynamically adjust the cross-linking density of the hydrogel matrix based on glucose concentration, creating a feedback loop that allows the system to respond adaptively to changing physiological conditions while maintaining prolonged insulin delivery
Solution Approach 2:
The patent transforms the static, continuous release mechanism into a dynamic system where the cross-linking density and mesh size of the hydrogel matrix can change in response to glucose levels. The multivalent cross-linking agents exhibit dynamic binding and unbinding behavior that modulates insulin release rates, enabling the system to adapt its release characteristics to varying physiological needs
3Reliability
If terminally functionalized polymerdrug conjugates are used, then greater retention of in vivo bioactivity is achieved versus randomly functionalized conjugates, but the manufacturing precision requirements increase
Solution Approach 1:
The patent segments the functionalization process into distinct stages: first synthesizing the carbohydrate polymer backbone with terminal functional groups, then separately introducing the insulin drug molecules through controlled conjugation reactions. This segmentation allows for better control over the positioning and stoichiometry of drug molecules, maintaining high bioactivity while simplifying the manufacturing process compared to attempting simultaneous random functionalization
Solution Approach 2:
The patent performs preliminary functionalization of the carbohydrate polymer backbone with reactive terminal groups before conjugating the insulin drug molecules. This preliminary action creates a well-defined scaffold that directs subsequent drug attachment to specific terminal positions, ensuring uniform distribution and optimal orientation of insulin molecules without requiring high manufacturing precision during the final conjugation step
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These conjugates enable controlled and proportional release of insulin in response to glucose levels, improving bioactivity and pharmacokinetic properties, reducing enzymatic degradation, and overcoming production challenges of natural polymers, while maintaining bioactivity and pharmacodynamic properties similar to unconjugated insulin.
Implementation Method 1
The non-covalent bonds between the multivalent cross-linking agents and the affinity ligands are competitively dissociated in the presence of excess amounts of the target molecule
Implementation Method 2
combining the conjugates with multivalent cross-linking agents that non-covalently bind the affinity ligands of the conjugates and thereby cross-link the conjugates to form the cross-linked material
Implementation Method 3
The non-covalent bonds between the multivalent cross-linking agents and the affinity ligands are competitively dissociated in the presence of excess amounts of the target molecule
Data Source
AI summary
The present disclosure provides inter alia conjugates of formula (I):wherein n, R1, R2, Rx, Z, X, Y and Z are as defined herein. A conjugate of formula (I) can also be converted to a conjugate of formulae (II) or (III) as described herein. Without limitation, the conjugates can be used to make controlled release materials and chemical sensors.